{"id":70291,"date":"2026-07-20T14:39:11","date_gmt":"2026-07-20T06:39:11","guid":{"rendered":"https:\/\/flcube.com\/?p=70291"},"modified":"2026-07-20T14:39:12","modified_gmt":"2026-07-20T06:39:12","slug":"chinas-nmpa-suspends-medochemies-tramadol-hydrochloride-capsules-following-non-compliant-overseas-inspection-and-documentation-failure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70291","title":{"rendered":"China&#8217;s NMPA Suspends Medochemie&#8217;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China&#8217;s National Medical Products Administration (NMPA)<\/strong> announced the <strong>immediate suspension<\/strong> of <strong>import, sale, and use<\/strong> of <strong>Tramadol Hydrochloride Capsules<\/strong> manufactured by <strong>Medochemie Ltd.<\/strong> of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company&#8217;s <strong>failure to submit required authorization documents<\/strong> within the prescribed timeframe for an <strong>overseas on-site dynamic inspection<\/strong> under China&#8217;s <strong>2026 annual foreign drug inspection plan<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-enforcement-details\" class=\"wp-block-heading\">Regulatory Enforcement Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Affected Product<\/strong><\/td><td>Tramadol Hydrochloride Capsules<\/td><\/tr><tr><td><strong>Manufacturer<\/strong><\/td><td>Medochemie Ltd., Cyprus<\/td><\/tr><tr><td><strong>Registration Number<\/strong><\/td><td>HJ20140362<\/td><\/tr><tr><td><strong>Enforcement Action<\/strong><\/td><td>Suspension of import, sale, and use<\/td><\/tr><tr><td><strong>Additional Measure<\/strong><\/td><td>Immediate suspension of import permit issuance<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>10 Jul 2026 (immediate)<\/td><\/tr><tr><td><strong>Legal Basis<\/strong><\/td><td>Drug Administration Law and Provisions for the Overseas Inspection of Drugs and Medical Devices<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-inspection-compliance-framework\" class=\"wp-block-heading\">Inspection Compliance Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inspection Program:<\/strong> 2026 Annual Foreign Drug Inspection Plan<\/li>\n\n\n\n<li><strong>Inspection Type:<\/strong> Overseas on-site dynamic inspection<\/li>\n\n\n\n<li><strong>Documentation Requirement:<\/strong> Authorization documents submission within prescribed timeframe<\/li>\n\n\n\n<li><strong>Company Response:<\/strong> Failed to meet documentation deadline<\/li>\n\n\n\n<li><strong>Inspection Outcome:<\/strong> Deemed &#8220;<strong>non-compliant<\/strong>&#8221; by NMPA<\/li>\n\n\n\n<li><strong>Enforcement Trigger:<\/strong> Documentation failure combined with non-compliant inspection status<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-assessment\" class=\"wp-block-heading\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Medochemie Ltd.<\/strong><\/td><td>Complete market exclusion from China; potential revenue loss of $15-25 million annually; reputational damage affecting other markets<\/td><\/tr><tr><td><strong>Chinese Hospitals &amp; Pharmacies<\/strong><\/td><td>Immediate supply disruption for tramadol hydrochloride capsules; need for alternative analgesic sourcing<\/td><\/tr><tr><td><strong>Patients<\/strong><\/td><td>Potential treatment continuity issues for chronic pain management; forced switching to alternative medications<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Domestic Chinese manufacturers and compliant international suppliers benefit from immediate market opportunity<\/td><\/tr><tr><td><strong>Import Distributors<\/strong><\/td><td>Inventory write-downs and contract termination risks; supply chain reconfiguration required<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-regulatory-precedent-amp-industry-implications\" class=\"wp-block-heading\">Regulatory Precedent &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enforcement Trend:<\/strong> Part of NMPA&#8217;s strengthened oversight of foreign drug manufacturers under revised Drug Administration Law<\/li>\n\n\n\n<li><strong>Documentation Standards:<\/strong> Highlights NMPA&#8217;s zero-tolerance approach to procedural compliance failures<\/li>\n\n\n\n<li><strong>Supply Chain Risk:<\/strong> Demonstrates vulnerability of single-source foreign drug dependencies in Chinese market<\/li>\n\n\n\n<li><strong>Quality Assurance:<\/strong> Reinforces NMPA&#8217;s commitment to maintaining drug quality standards equivalent to domestic products<\/li>\n\n\n\n<li><strong>Market Access Strategy:<\/strong> Foreign manufacturers must prioritize China regulatory compliance as critical business function<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-alternative-supply-options\" class=\"wp-block-heading\">Alternative Supply Options<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product Category<\/th><th>Available Alternatives<\/th><th>Market Readiness<\/th><\/tr><\/thead><tbody><tr><td><strong>Tramadol Hydrochloride (Generic)<\/strong><\/td><td>Multiple domestic Chinese manufacturers<\/td><td>Immediate availability<\/td><\/tr><tr><td><strong>Other Opioid Analgesics<\/strong><\/td><td>Codeine, oxycodone, morphine formulations<\/td><td>Established supply chains<\/td><\/tr><tr><td><strong>Non-Opioid Analgesics<\/strong><\/td><td>NSAIDs, acetaminophen combinations<\/td><td>Widely available<\/td><\/tr><tr><td><strong>Branded Tramadol<\/strong><\/td><td>Other international manufacturers with compliant status<\/td><td>Limited availability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-recommendations-for-industry\" class=\"wp-block-heading\">Strategic Recommendations for Industry<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Foreign Manufacturers:<\/strong> Implement dedicated China regulatory compliance teams with real-time monitoring of NMPA requirements<\/li>\n\n\n\n<li><strong>Importers\/Distributors:<\/strong> Diversify supplier base to mitigate single-manufacturer risk exposure<\/li>\n\n\n\n<li><strong>Healthcare Institutions:<\/strong> Develop contingency formularies for critical medications with foreign-only sources<\/li>\n\n\n\n<li><strong>Regulatory Affairs:<\/strong> Establish proactive communication channels with NMPA to address compliance issues before enforcement actions<\/li>\n\n\n\n<li><strong>Quality Systems:<\/strong> Invest in robust documentation management systems meeting Chinese regulatory standards<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory enforcement, market impacts, and compliance requirements. Actual outcomes may differ due to risks including regulatory interpretation variations, market adaptation speed, and competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70292,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[14],"class_list":["post-70291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NMPA Suspends Medochemie&#039;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company&#039;s failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China&#039;s 2026 annual foreign drug inspection plan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70291\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NMPA Suspends Medochemie&#039;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company&#039;s failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China&#039;s 2026 annual foreign drug inspection plan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70291\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:39:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T06:39:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NMPA Suspends Medochemie&#8217;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure\",\"datePublished\":\"2026-07-20T06:39:11+00:00\",\"dateModified\":\"2026-07-20T06:39:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2002.webp\",\"keywords\":[\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70291#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70291\",\"name\":\"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2002.webp\",\"datePublished\":\"2026-07-20T06:39:11+00:00\",\"dateModified\":\"2026-07-20T06:39:12+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company's failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China's 2026 annual foreign drug inspection plan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70291\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2002.webp\",\"width\":1080,\"height\":608,\"caption\":\"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70291#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NMPA Suspends Medochemie&#8217;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company's failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China's 2026 annual foreign drug inspection plan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70291","og_locale":"en_US","og_type":"article","og_title":"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure","og_description":"China's National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company's failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China's 2026 annual foreign drug inspection plan.","og_url":"https:\/\/flcube.com\/?p=70291","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T06:39:11+00:00","article_modified_time":"2026-07-20T06:39:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70291#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70291"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NMPA Suspends Medochemie&#8217;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure","datePublished":"2026-07-20T06:39:11+00:00","dateModified":"2026-07-20T06:39:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70291"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","keywords":["NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70291#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70291","url":"https:\/\/flcube.com\/?p=70291","name":"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70291#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","datePublished":"2026-07-20T06:39:11+00:00","dateModified":"2026-07-20T06:39:12+00:00","description":"China's National Medical Products Administration (NMPA) announced the immediate suspension of import, sale, and use of Tramadol Hydrochloride Capsules manufactured by Medochemie Ltd. of Cyprus (Registration No.: HJ20140362). The enforcement action follows the company's failure to submit required authorization documents within the prescribed timeframe for an overseas on-site dynamic inspection under China's 2026 annual foreign drug inspection plan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70291#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70291"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70291#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","width":1080,"height":608,"caption":"China's NMPA Suspends Medochemie's Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70291#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NMPA Suspends Medochemie&#8217;s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70291"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70291\/revisions"}],"predecessor-version":[{"id":70293,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70291\/revisions\/70293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70292"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}